ALESSANDRO GOZZETTI*, MONICA BOCCHIA
Oncology Research, Vol.31, No.3, pp. 271-274, 2023, DOI:10.32604/or.2023.028668
- 22 May 2023
Abstract Novel drug availability has increased the depth of response and revolutionised the outcomes of multiple
myeloma patients. Minimal residual disease evaluation is a surrogate for progression-free survival and overall survival
and has become widely used not-only in clinical trials but also in daily patient management. Bone marrow aspiration
is the gold standard for response evaluation, but due to the patchy nature of myeloma, false negatives are possible.
Liquid biopsy and blood-based minimal residual disease evaluation consider circulating plasma cells, mass
spectrometry or circulating tumour DNA. This approach is less invasive, can provide a more comprehensive More >
Login
Register
